Skip to main content
. 2020 May 13;368(6496):1274–1278. doi: 10.1126/science.abc2241

Fig. 3. The protection efficiency of mAbs in hACE2 mice model after infection with COVID-19 virus.

Fig. 3

(A) Body weight loss was recorded for PBS, B38 treatment, and H4 treatment groups (for all groups, n = 4 mice). All the mice were challenged intranasally with COVID-19 virus, and a 25 mg/kg dose of antibodies was injected (intraperitoneally) 12 hours after infection. Equal volume of PBS was used as a control. The weight loss was recorded over 3 days, and a significant difference could be observed between the B38 group and the PBS group (unpaired t test, ***P < 0.001). (B) The virus titer in lungs of three groups was determined at 3 dpi by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). The mAb treatment group reduced the viral load in the lungs of mice (unpaired t test, ***P < 0.001). (C to H) Representative histopathology of the lungs in COVID-19 virus–infected hACE2 mice (3 dpi). Severe bronchopneumonia and interstitial pneumonia was observed in the PBS group [(C) and (F)], with edema and bronchial epithelial cell desquamation (black arrow) and infiltration of lymphocytes within alveolar spaces (red arrow). Mild bronchopneumonia was observed in the H4 group [(E) and (H)], whereas no lesions were observed in the B38 group [(D) and (G)]. The images and areas of interest (red boxes) are magnified 100× and 400×, respectively.